


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN	LIRAGLUTIDE
PRONUNCIATION	lir a' gloo tide
THERAPEUTIC CLAIM	Adjunctive therapy to improve glycemic control, with diet and exercise, in patients with type II diabetes

CHEMICAL NAMES

1. Glycine, L-histidyl-L-alanyl-L- α -glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L- α -aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L- α -glutamylglycyl-L-glutaminy-L-alanyl-L-alanyl- N^6 -[N-(1-oxohexadecyl)-L- γ -glutamyl]-L-lysyl-L- α -glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-
2. $N^{\epsilon 26}$ -(N-hexadecanoyl-L- γ -glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
3. Arg³⁴Lys²⁶-(N- ϵ -(γ -Glu(N- α -hexadecanoyl)))-GLP-1[7-37]

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₁₇₂ H ₂₆₅ N ₄₃ O ₅₁
MOLECULAR WEIGHT	3751.20 Da
CODE	NNC 90-1170, NN2211
TRADEMARK	None
MANUFACTURER	Novo Nordisk A/S
CAS REGISTRY NUMBER	204656-20-2